Compare DexCom, Inc. (DXCM) vs Lemonade Inc (LMND) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

LMND trades at $70.14, down 0.68% on the day, with a bullish technical signal supported by moving averages. The company shows accelerating revenue growth, reaching $737.9M in 2025, while narrowing net losses. Recent expansion into new states and a renegotiated reinsurance program highlight operational momentum, though profitability remains negative.

The outlook balances growth potential against persistent losses. Investment appeal hinges on continued premium expansion and path to profitability, but risks include high valuation multiples and competitive pressures. Analyst sentiment is mixed, with a $69.60 consensus target slightly below the current price.